{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:19:49Z","timestamp":1773231589114,"version":"3.50.1"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113717","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T23:39:47Z","timestamp":1734133187000},"page":"113717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice"],"prefix":"10.1016","volume":"146","author":[{"given":"Sijia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/JLB.1MR0720-185RR","article-title":"The role of ubiquitinase in B cell development and function","volume":"109","author":"Zhang","year":"2021","journal-title":"J Leukoc Biol"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0010","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1038\/bcj.2015.89","article-title":"Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas","volume":"5","author":"Lunning","year":"2015","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.cco.0000174040.52427.83","article-title":"Current status of therapeutic vaccines for non-Hodgkin's lymphoma","volume":"17","author":"Hurvitz","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.intimp.2024.113717_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1266721","article-title":"Comprehensive scientometrics and visualization study profiles lymphoma metabolism and identifies its significant research signatures","volume":"14","author":"Guo","year":"2023","journal-title":"Front Endocrinol (lausanne)"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0025","doi-asserted-by":"crossref","first-page":"14131","DOI":"10.18632\/aging.203030","article-title":"Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients","volume":"13","author":"Zhao","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"suppl 5","key":"10.1016\/j.intimp.2024.113717_b0030","doi-asserted-by":"crossref","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","article-title":"Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Vitolo","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0035","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.intimp.2024.113717_b0040","first-page":"4660","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int J Surg"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0050","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"50","key":"10.1016\/j.intimp.2024.113717_b0055","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032333","article-title":"Efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials","volume":"101","author":"Guan","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"24","key":"10.1016\/j.intimp.2024.113717_b0065","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course","volume":"22","author":"Nishino","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0070","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0075","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/jha2.112","article-title":"Fidelity of peripheral blood for monitoring genomics and tumor immune-microenvironment in myelodysplastic syndromes","volume":"1","author":"Lee","year":"2020","journal-title":"Ejhaem"},{"issue":"6127","key":"10.1016\/j.intimp.2024.113717_b0080","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"issue":"5256","key":"10.1016\/j.intimp.2024.113717_b0085","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.intimp.2024.113717_b0090","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1158\/0008-5472.CAN-16-0342","article-title":"CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity","volume":"77","author":"Herrmann","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2024.113717_b0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0105","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri1349","article-title":"Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity","volume":"4","author":"Chen","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.intimp.2024.113717_b0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation","volume":"19","author":"Salomon","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.intimp.2024.113717_b0115","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0120","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.leu.2403907","article-title":"Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia","volume":"19","author":"Motta","year":"2005","journal-title":"Leukemia"},{"issue":"18 Pt 1","key":"10.1016\/j.intimp.2024.113717_b0125","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1158\/1078-0432.CCR-07-0283","article-title":"ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia","volume":"13","author":"Joshi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.intimp.2024.113717_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2020.102112","article-title":"CTLA4 mRNA expression in blood is lower in schizophrenia, but not in affective disorders","volume":"52","author":"Miyamoto","year":"2020","journal-title":"Asian J Psychiatr"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.23398","article-title":"CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy","volume":"88","author":"Keane","year":"2013","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0140","doi-asserted-by":"crossref","first-page":"e558","DOI":"10.1038\/bcj.2017.37","article-title":"Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma","volume":"7","author":"Kusano","year":"2017","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0145","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0150","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/art.24181","article-title":"CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice","volume":"60","author":"Kolar","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2024.113717_b0160","article-title":"Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma","volume":"14","author":"Bao","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0165","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0170","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J Immunol"},{"issue":"20","key":"10.1016\/j.intimp.2024.113717_b0175","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.intimp.2024.113717_b0180","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0185","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1078-0432.CCR-16-0040","article-title":"CTLA-4 Limits Anti-CD20-Mediated Tumor Regression","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0195","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1007\/s12032-012-0176-1","article-title":"Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients","volume":"29","author":"Dehghani","year":"2012","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ejh.12144","article-title":"Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma","volume":"91","author":"G\u0142owala-Kosi\u0144ska","year":"2013","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0205","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00262-020-02591-y","article-title":"Aberrant peripheral blood CD4(+) CD25(+) FOXP3(+) regulatory T cells\/T helper-17 number is associated with the outcome of patients with lymphoma","volume":"69","author":"Dehghani","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0210","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.175.7.4180","article-title":"Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells","volume":"175","author":"Lim","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0215","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2011.03439.x","article-title":"Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro","volume":"133","author":"Lindqvist","year":"2011","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0220","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2567.2011.03539.x","article-title":"T regulatory cells in B-cell malignancy - tumour support or kiss of death?","volume":"135","author":"Lindqvist","year":"2012","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0225","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0230","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0235","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0240","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0245","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.intimp.2024.113717_b0250","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0260","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s13277-015-4217-1","article-title":"Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody","volume":"37","author":"Ciszak","year":"2016","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tips.2019.11.003","article-title":"Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy","volume":"41","author":"Liu","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0270","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"Embo j"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0275","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1095\/biolreprod.105.046581","article-title":"Trophoblast CD274 (B7-H1) is differentially expressed across gestation: influence of oxygen concentration","volume":"74","author":"Holets","year":"2006","journal-title":"Biol Reprod"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0280","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.4049\/jimmunol.169.10.5538","article-title":"Expression of programmed death 1 ligands by murine T cells and APC","volume":"169","author":"Yamazaki","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.blre.2015.11.003","article-title":"Immune checkpoint blockade: Releasing the brake towards hematological malignancies","volume":"30","author":"Xia","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.intimp.2024.113717_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105999","article-title":"Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma","volume":"77","author":"Xie","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"19","key":"10.1016\/j.intimp.2024.113717_b0295","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.intimp.2024.113717_b0300","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0305","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0310","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0315","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1155\/2010\/404069","article-title":"Diagnostic and prognostic utility of PD-1 in B cell lymphomas","volume":"29","author":"Muenst","year":"2010","journal-title":"Dis Markers"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0325","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.intimp.2024.113717_b0330","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0335","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00281-019-00744-5","article-title":"CD8(+) T cell exhaustion","volume":"41","author":"Kurachi","year":"2019","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0340","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","article-title":"Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes","volume":"116","author":"Kondo","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0345","first-page":"1407","article-title":"The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer","volume":"18","author":"Henick","year":"2014","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0350","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/ni1129","article-title":"Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity","volume":"5","author":"Smith","year":"2004","journal-title":"Nat Immunol"},{"issue":"6925","key":"10.1016\/j.intimp.2024.113717_b0355","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nature01441","article-title":"CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes","volume":"421","author":"Janssen","year":"2003","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nri.2015.10","article-title":"The multifaceted role of CD4(+) T cells in CD8(+) T cell memory","volume":"16","author":"Laidlaw","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"5617","key":"10.1016\/j.intimp.2024.113717_b0365","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.1082305","article-title":"Requirement for CD4 T cell help in generating functional CD8 T cell memory","volume":"300","author":"Shedlock","year":"2003","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0370","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/cam4.874","article-title":"PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma","volume":"5","author":"Zhang","year":"2016","journal-title":"Cancer Med"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0375","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41375-022-01649-3","article-title":"A phase two study of high dose blinatumomab in Richter's syndrome","volume":"36","author":"Thompson","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0380","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"issue":"16","key":"10.1016\/j.intimp.2024.113717_b0385","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/bloodadvances.2022007493","article-title":"Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma","volume":"6","author":"Colombo","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0390","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.intimp.2024.113717_b0395","article-title":"The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.intimp.2024.113717_b0400","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s40265-021-01628-5","article-title":"Zimberelimab: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0405","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100977","article-title":"Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation","volume":"14","author":"Hodkinson","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.intimp.2024.113717_b0415","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3389\/fonc.2018.00351","article-title":"Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma","volume":"8","author":"Zhang","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0420","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.113717_b0425","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520945075","article-title":"Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed\/refractory primary mediastinal B-cell lymphoma: a case report and literature review","volume":"48","author":"Huang","year":"2020","journal-title":"J Int Med Res"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0430","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00277-020-04042-1","article-title":"Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab","volume":"100","author":"Sim","year":"2021","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0435","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.21037\/atm-20-6833","article-title":"Immune checkpoint inhibitors in lymphoma: challenges and opportunities","volume":"9","author":"Hatic","year":"2021","journal-title":"Ann Transl Med"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0440","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1007\/s00277-024-05739-3","article-title":"Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK\/T cell lymphoma","volume":"103","author":"Yoon","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.intimp.2024.113717_b0445","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.884091","article-title":"Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience","volume":"12","author":"Polg\u00e1rov\u00e1","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0450","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2024.113717_b0455","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.19844","article-title":"Checkpoint inhibition in macroglobulinaemia","author":"Kapoor","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0460","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0465","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/ajh.26922","article-title":"A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer\/T-cell lymphoma","volume":"98","author":"Sun","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.intimp.2024.113717_b0470","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.608304","article-title":"Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK\/T-Cell Lymphoma: Case Report and Literature Review","volume":"10","author":"Yan","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0475","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0480","first-page":"4570","article-title":"Salvage camrelizumab for an intractable NK\/T cell lymphoma patient with two instances of intestinal perforation: a case report and literature review","volume":"27","author":"Xia","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.intimp.2024.113717_b0485","article-title":"Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.intimp.2024.113717_b0490","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0495","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008553","article-title":"Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed\/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China","volume":"12","author":"Yu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.113717_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.706865","article-title":"Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T\/NK Cell Lymphoma: A Case Report","volume":"11","author":"Xia","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0505","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13256-021-02740-6","article-title":"Atezolizumab in combination with intrathecal chemotherapy and radiation for treatment of isolated cerebral nervous system relapse in a patient with extranodal NK\/T cell lymphoma: a case report","volume":"15","author":"Lipsitt","year":"2021","journal-title":"J Med Case Rep"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0510","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00432-021-03847-5","article-title":"Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed\/refractory follicular and diffuse large B-cell lymphoma","volume":"149","author":"Topp","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0515","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/10428194.2021.2015765","article-title":"A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenstr\u00f6m's macroglobulinemia","volume":"63","author":"Panayiotidis","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.intimp.2024.113717_b0520","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jid.2023.02.017","article-title":"Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma","volume":"143","author":"Han","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0525","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-023-05475-0","article-title":"A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed\/refractory follicular lymphoma","volume":"103","author":"Merryman","year":"2024","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1016\/j.intimp.2024.113717_b0530","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0535","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0540","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0545","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2024.113717_b0550","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-015-0142-z","article-title":"Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment","volume":"12","author":"Juno","year":"2015","journal-title":"Retrovirology"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0555","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0560","first-page":"327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein","volume":"176","author":"Baixeras","year":"1992","journal-title":"A New Ligand for Human Leukocyte Antigen Class II Antigens, J Exp Med"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0565","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"10.1016\/j.intimp.2024.113717_b0570","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"issue":"6307","key":"10.1016\/j.intimp.2024.113717_b0575","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah3374","article-title":"Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0580","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1756116","article-title":"Genomic and immunologic correlates of LAG-3 expression in cancer","volume":"9","author":"Panda","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2024.113717_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1265255","article-title":"Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0590","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1111\/ajco.13730","article-title":"The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes","volume":"18","author":"Shokrgozar","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5\u20136","key":"10.1016\/j.intimp.2024.113717_b0595","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0600","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-024-01991-3","article-title":"Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1\/PD-L1 axis blockade via Id1 downregulation","volume":"23","author":"Puyalto","year":"2024","journal-title":"Mol Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2024.113717_b0605","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0610","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0615","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat. Med."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.113717_b0620","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2022-166670","article-title":"Updated Results from an Open-Label Phase 1\/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment","volume":"140","author":"Timmerman","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.113717_b0625","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2021-151728","article-title":"Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study","volume":"138","author":"Yusuf","year":"2021","journal-title":"Blood"},{"issue":"13_Supplement","key":"10.1016\/j.intimp.2024.113717_b0630","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/1538-7445.AM2021-1583","article-title":"Abstract 1583: SEA-TGT is an empowered anti-TIGIT antibody that displays superior combinatorial activity with several therapeutic agents","volume":"81","author":"Smith","year":"2021","journal-title":"Cancer Res."},{"issue":"8_Supplement","key":"10.1016\/j.intimp.2024.113717_b0635","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT265","article-title":"Abstract CT265: Phase 1 dose-escalation study of SGN-TGT monotherapy in patients with advanced malignancies","volume":"83","author":"Cabanas","year":"2023","journal-title":"Cancer Res."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.113717_b0640","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood-2021-147773","article-title":"Biomarker Analysis of a Phase Ia\/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R\/R) B-Cell Non-Hodgkin Lymphoma (NHL)","volume":"138","author":"Ruppert","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.113717_b0645","doi-asserted-by":"crossref","first-page":"v488","DOI":"10.1093\/annonc\/mdz253.023","article-title":"1197P - A phase I study of Sym021, an anti-PD-1 antibody","volume":"30","author":"Spreafico","year":"2019","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2024.113717_b0650","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-19-3548","article-title":"FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity","volume":"26","author":"Kraman","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.intimp.2024.113717_b0655","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood-2017-06-792267","article-title":"Dual PD1\/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia","volume":"131","author":"Wierz","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0660","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"issue":"49","key":"10.1016\/j.intimp.2024.113717_b0665","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc2728","article-title":"Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding","volume":"5","author":"Andrews","year":"2020","journal-title":"Sci Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0670","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6871","key":"10.1016\/j.intimp.2024.113717_b0675","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2024.113717_b0680","article-title":"Regulating the regulatory T cells as cell therapies in autoimmunity and cancer","volume":"10","author":"Hosseinalizadeh","year":"2023","journal-title":"Front Med (lausanne)"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0685","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.20090397","article-title":"Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion","volume":"207","author":"Huang","year":"2010","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0690","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065616","article-title":"Galectin-9 activates and expands human T-helper 1 cells","volume":"8","author":"Gooden","year":"2013","journal-title":"PLoS One"},{"issue":"7534","key":"10.1016\/j.intimp.2024.113717_b0700","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.intimp.2024.113717_b0705","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1042\/BCJ20210425","article-title":"Phosphatidylserine binding directly regulates TIM-3 function","volume":"478","author":"Smith","year":"2021","journal-title":"Biochem J"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0710","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells","volume":"184","author":"DeKruyff","year":"2010","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.intimp.2024.113717_b0715","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","article-title":"Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation","volume":"113","author":"Nakayama","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0720","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2024.113717_b0725","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6968595","article-title":"Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3(+) CD8(+) T Cells and Survival in Diffuse Large B Cell Lymphoma","volume":"2020","author":"Zhang","year":"2020","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.intimp.2024.113717_b0735","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biopha.2015.08.037","article-title":"Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma","volume":"75","author":"Zhang","year":"2015","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"10","key":"10.1016\/j.intimp.2024.113717_b0740","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"33","key":"10.1016\/j.intimp.2024.113717_b0745","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.intimp.2024.113717_b0750","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0755","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100013R","article-title":"Activated Galectin-9\/Tim3 promotes Treg and suppresses Th1 effector function in chronic lymphocytic leukemia","volume":"35","author":"Pang","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2024.113717_b0760","doi-asserted-by":"crossref","unstructured":"W.J. Simmons, M. Koneru, M. Mohindru, R. Thomas, S. Cutro, P. Singh, R.H. Dekruyff, G. Inghirami, A.J. Coyle, B.S. Kim, N.M. Ponzio, Tim-3+ T-bet+ tumor-specific Th1 cells colocalize with and inhibit development and growth of murine neoplasms, Journal of immunology (Baltimore, Md. : 1950) 174(3) (2005) 1405-15.","DOI":"10.4049\/jimmunol.174.3.1405"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0765","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.intimp.2024.113717_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107662","article-title":"High levels of Tim-3(+)Foxp3(+)Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients","volume":"96","author":"Zhong","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0775","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23849","article-title":"TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer","volume":"2","author":"Sakuishi","year":"2013","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.intimp.2024.113717_b0780","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0785","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI45138","article-title":"Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs","volume":"122","author":"Gupta","year":"2012","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.intimp.2024.113717_b0790","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2024.113717_b0795","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nm.3179","article-title":"Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells","volume":"19","author":"Gagliani","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.intimp.2024.113717_b0800","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/ncomms5741","article-title":"Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy","volume":"5","author":"Burton","year":"2014","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0805","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/eji.200839116","article-title":"A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC","volume":"39","author":"Boles","year":"2009","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0810","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10238-022-00817-0","article-title":"TIGIT axis: novel immune checkpoints in anti-leukemia immunity","volume":"23","author":"Qiu","year":"2023","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0815","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0820","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000266","article-title":"Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity","volume":"8","author":"Reches","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0825","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030200","article-title":"TIGIT\/CD226 Axis Regulates Anti-Tumor Immunity","volume":"14","author":"Yeo","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0830","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/gut.49.2.236","article-title":"Overexpression of the CD155 gene in human colorectal carcinoma","volume":"49","author":"Masson","year":"2001","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0835","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00262-018-2246-5","article-title":"TIGIT: a novel immunotherapy target moving from bench to bedside","volume":"67","author":"Solomon","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0840","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1084\/jem.20030788","article-title":"Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule","volume":"198","author":"Bottino","year":"2003","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0845","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1084\/jem.20150785","article-title":"Identification of CD112R as a novel checkpoint for human T cells","volume":"213","author":"Zhu","year":"2016","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.intimp.2024.113717_b0850","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/PAS.0000000000002168","article-title":"TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy","volume":"48","author":"Libert","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0855","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1038\/s41598-021-86655-8","article-title":"A novel scoring system for TIGIT expression in classic Hodgkin lymphoma","volume":"11","author":"Annibali","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0860","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.immuni.2014.02.012","article-title":"Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses","volume":"40","author":"Joller","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0865","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.intimp.2024.113717_b0870","first-page":"127","article-title":"Tim-3, Lag-3, and TIGIT","volume":"410","author":"Joller","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113717_b0875","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006582","article-title":"TIGIT is a key inhibitory checkpoint receptor in lymphoma","volume":"11","author":"Godfrey","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"39","key":"10.1016\/j.intimp.2024.113717_b0880","doi-asserted-by":"crossref","first-page":"63669","DOI":"10.18632\/oncotarget.11611","article-title":"Expression of immune checkpoints in T cells of esophageal cancer patients","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.113717_b0885","doi-asserted-by":"crossref","unstructured":"F. Comito, R. Pagani, G. Grilli, F. Sperandi, A. Ardizzoni, B. Melotti, Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma, Cancers (Basel) 14(2) (2022).","DOI":"10.3390\/cancers14020271"},{"issue":"6","key":"10.1016\/j.intimp.2024.113717_b0890","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0895","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.intimp.2024.113717_b0900","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.699895","article-title":"TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front Immunol"},{"issue":"26","key":"10.1016\/j.intimp.2024.113717_b0905","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0910","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0915","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.intimp.2024.113717_b0920","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.113717_b0925","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2024.113717_b0930","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: phase 1b PORTIA study results","volume":"7","author":"Jaeger","year":"2023","journal-title":"Blood Adv."},{"issue":"14","key":"10.1016\/j.intimp.2024.113717_b0935","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.113717_b0940","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","article-title":"Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma","volume":"12","author":"Jackson","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.intimp.2024.113717_b0945","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells","volume":"30","author":"Lee","year":"2022","journal-title":"Molecular Therapy : the Journal of the American Society of Gene Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0950","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1186\/s12967-024-05552-6","article-title":"Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy","volume":"22","author":"Su","year":"2024","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.intimp.2024.113717_b0955","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0960","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1926762","article-title":"Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients","volume":"10","author":"Machiraju","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113717_b0965","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1038\/s41467-022-32627-z","article-title":"scRNA-seq of gastric tumor shows complex intercellular interaction with an alternative T cell exhaustion trajectory","volume":"13","author":"Sun","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2024.113717_b0970","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed\/Refractory B-Cell Non-hodgkin Lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.intimp.2024.113717_b0975","first-page":"4415","article-title":"CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma: A case report","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol Lett"},{"issue":"10\u201312","key":"10.1016\/j.intimp.2024.113717_b0980","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/15384047.2021.1967083","article-title":"Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review","volume":"22","author":"Zheng","year":"2021","journal-title":"Cancer Biol Ther"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924022392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924022392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T16:48:32Z","timestamp":1736614112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924022392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":196,"alternative-id":["S1567576924022392"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113717","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoints in B-cell Lymphoma: Still an Unmet challenge from Basic research to clinical practice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113717"}}